{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:29:07Z","timestamp":1793654947271,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cgh.2026.09.038","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:46:22Z","timestamp":1791330382000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Advanced Therapies as Induction Therapy for Ulcerative Colitis: An Updated Systematic Review and Network Meta-Analysis"],"prefix":"10.1016","author":[{"given":"Pablo A.","family":"Olivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Lasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathurin","family":"Fumery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.09.038_bib1","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.09.038_bib2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.09.038_bib4","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning","author":"Fudman","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.038_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.038_bib6","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","volume":"71","author":"Burr","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.09.038_bib7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.038_bib8","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA Living Clinical Practice Guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib10","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2026.09.038_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.cgh.2026.09.038_bib12","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jrsm.1188","article-title":"The design-by-treatment interaction model: a unifying framework for modelling loop inconsistency in network meta-analysis","volume":"7","author":"Jackson","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cgh.2026.09.038_bib13","doi-asserted-by":"crossref","DOI":"10.18637\/jss.v106.i02","article-title":"Netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.cgh.2026.09.038_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.cgh.2026.09.038_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jclinepi.2016.02.016","article-title":"The rank-heat plot is a novel way to present the results from a network meta-analysis including multiple outcomes","volume":"76","author":"Veroniki","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.cgh.2026.09.038_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.09.038_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"Cinema: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib18","doi-asserted-by":"crossref","first-page":"i73","DOI":"10.1093\/ecco-jcc\/jjad212.0042","article-title":"DOP02 developing explicit thresholds for outcomes to inform (GRADE) evidence to decision frameworks for Inflammatory Bowel Disease guidelines","volume":"18","author":"Shaban","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.09.038_bib19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2026.09.038_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.038_bib21","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.09.038_bib23","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.09.038_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib25","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","article-title":"First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis\u2014results from a multicenter prospective randomized controlled trial and its post hoc analysis","volume":"51","author":"Kobayashi","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.038_bib27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/MCG.0000000000000319","article-title":"Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis","volume":"49","author":"Jiang","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.038_bib28","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib29","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib30","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib31","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.09.038_bib32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib34","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a Phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2026.09.038_bib35","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.09.038_bib37","doi-asserted-by":"crossref","first-page":"S-817","DOI":"10.1016\/S0016-5085(24)02359-X","article-title":"Su1795 Ozanimod as induction and maintenance therapy for ulcerative colitis: a randomized, double-blind, placebo-controlled study in Japan (J-TRUE NORTH)","volume":"166","author":"Nakase","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2026.09.038_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.038_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2026.09.038_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(25)00198-0","article-title":"Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","author":"Wu","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.09.038_bib42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00535-025-02216-0","article-title":"First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study","volume":"60","author":"Naganuma","year":"2025","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.038_bib43","article-title":"OP38 Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI)","volume":"19","author":"Bouguen","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.09.038_bib44","article-title":"Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from two, phase 3, randomised, double-blind, placebo- controlled, 8-week induction trials (ABTECT-1 & 2)","volume":"13","author":"Sands","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2026.09.038_bib45","article-title":"Efficacy of obefazimod in ABTECT Phase 3 induction trials: results of 8-week therapy in subsets of patients with and without prior inadequate response to advanced therapies","volume":"13","author":"Danese","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2026.09.038_bib46","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/ecco-jcc\/jjae190.0010","article-title":"OP10 Efficacy and safety of subcutaneous guselkumab induction therapy in patients with ulcerative Colitis: results through week 12 from the phase 3 ASTRO study","volume":"19","author":"Peyrin-Biroulet","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2026.09.038_bib47","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0001082824.10406.d0","article-title":"S73 subgroup analysis of ozanimod efficacy by prior biologic exposure in Japanese patients with ulcerative colitis from the phase 2\/3 J-True north study","volume":"119","author":"Nakase","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.09.038_bib48","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.gastro.2023.10.033","article-title":"Integrating evidence to guide use of biologics and small molecules for inflammatory bowel diseases","volume":"166","author":"Dulai","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib50","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2025.05.015","article-title":"An international consensus on appropriate management of corticosteroids in clinical trials in inflammatory bowel disease","author":"Han\u017eel","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.09.038_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-024-00989-y","article-title":"Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease","author":"Ma","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526007421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526007421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:59:29Z","timestamp":1793653169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526007421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":50,"alternative-id":["S1542356526007421"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.09.038","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Advanced Therapies as Induction Therapy for Ulcerative Colitis: An Updated Systematic Review and Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.09.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}